 |
|
|
| |
Early and Durable Reductions in Soluble CD14 Concentrations Among Treatment-Experienced Persons With HIV-1 Through
96 Weeks of Fostemsavir Treatment in a Phase 2b Clinical Trial
|
| |
| |
EACS 2023 oct 20
Elizabeth R. Wonderlich,1 Manyu Prakash,2 Andrew Clark,2 Jose R. Castillo-Mancilla,1 Neelanjana Ray,3 Marcia Wang,4 Max Lataillade,5 Allan R. Tenorio1
1ViiV Healthcare, Durham, NC, USA; 2ViiV Healthcare, Brentford, UK; 3Bristol Myers Squibb, Lawrenceville, NJ, USA;
4GSK, Collegeville, PA, USA; 5ViiV Healthcare, Branford, CT, USA
|
| |
|
|
|
|
|
